Nanobiotix S.A. (NBTX)
Nanobiotix S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Paris, IF, FR. The stock last traded at $39.63, up 2.34% on the session, giving a market capitalisation of $2.00B. On trailing twelve-month figures it carries a trailing P/E of -67.57, a net margin of -80.8%. Its beta of 0.57 implies it has historically moved less than the broad market.
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Nanobiotix S.A. is most often compared with the following Healthcare names: